| Year |
Citation |
Score |
| 2024 |
Panayi N, Schulz P, He P, Hanna B, Lifshitz J, Rowe RK, Sierks MR. Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits. Molecular Neurobiology. PMID 38411868 DOI: 10.1007/s12035-024-04035-5 |
0.349 |
|
| 2023 |
Panayi N, Schulz P, He P, Hanna B, Lifshitz J, Rowe R, Sierks MR. Traumatic brain injury in mice generates early-stage Alzheimer's disease related protein pathology that correlates with neurobehavioral deficits. Research Square. PMID 37205508 DOI: 10.21203/rs.3.rs-2865501/v1 |
0.347 |
|
| 2021 |
Trudler D, Nazor KL, Eisele YS, Grabauskas T, Dolatabadi N, Parker J, Sultan A, Zhong Z, Goodwin MS, Levites Y, Golde TE, Kelly JW, Sierks MR, Schork NJ, Karin M, et al. Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33833060 DOI: 10.1073/pnas.2025847118 |
0.309 |
|
| 2021 |
He P, Schulz P, Sierks MR. A conformation specific antibody against Oligomeric β-Amyloid Restores Neuronal Integrity in a Mouse Model of Alzheimer's Disease. The Journal of Biological Chemistry. 100241. PMID 33428939 DOI: 10.1074/jbc.RA120.015327 |
0.431 |
|
| 2020 |
He P, Schulz P, Sierks MR. A conformation specific antibody against Oligomeric β-Amyloid Restores Neuronal Integrity in a Mouse Model of Alzheimer's Disease. The Journal of Biological Chemistry. PMID 33376140 DOI: 10.1074/jbc.RA120.015327 |
0.431 |
|
| 2020 |
Venkataraman L, He P, Khan G, Harris BT, Sierks MR. Isolation and characterization of antibody fragments selective for human FTD brain derived TDP-43 variants. Bmc Neuroscience. 21: 36. PMID 32887544 DOI: 10.1186/S12868-020-00586-0 |
0.324 |
|
| 2020 |
Venkataraman L, He P, Schulz P, Sierks MR. Isolation and characterization of antibody fragment selective for human Alzheimer's disease brain-derived tau variants. Neurobiology of Aging. 94: 7-14. PMID 32497877 DOI: 10.1016/j.neurobiolaging.2020.04.014 |
0.381 |
|
| 2019 |
He P, Xin W, Schulz P, Sierks MR. Bispecific Antibody Fragment Targeting APP and Inducing α-Site Cleavage Restores Neuronal Health in an Alzheimer's Mouse Model. Molecular Neurobiology. PMID 31041656 DOI: 10.1007/s12035-019-1597-z |
0.448 |
|
| 2017 |
Roher AE, Kokjohn TA, Clarke SG, Sierks MR, Maarouf CL, Serrano GE, Sabbagh MS, Beach TG. APP/Aβ structural diversity and Alzheimer's disease pathogenesis. Neurochemistry International. PMID 28811267 DOI: 10.1016/J.Neuint.2017.08.007 |
0.45 |
|
| 2017 |
Williams SM, Schulz P, Rosenberry TL, Caselli RJ, Sierks MR. Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 28372328 DOI: 10.3233/JAD-161116 |
0.368 |
|
| 2016 |
Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, ... ... Sierks M, et al. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Scientific Reports. 6: 19393. PMID 26786552 DOI: 10.1038/Srep19393 |
0.549 |
|
| 2015 |
Williams SM, Schulz P, Sierks MR. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. The European Journal of Neuroscience. PMID 26332448 DOI: 10.1111/ejn.13056 |
0.379 |
|
| 2015 |
Williams SM, Venkataraman L, Tian H, Khan G, Harris BT, Sierks MR. Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis. Journal of Visualized Experiments : Jove. PMID 25742170 DOI: 10.3791/52584 |
0.533 |
|
| 2015 |
Tian H, Davidowitz E, Lopez P, He P, Schulz P, Moe J, Sierks MR. Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiology of Aging. 36: 1342-55. PMID 25616912 DOI: 10.1016/J.Neurobiolaging.2014.12.002 |
0.581 |
|
| 2014 |
Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S, Kosberg K, Shen J, Rockenstein E, Patrick C, Adame A, Gonzalez T, Sierks M, Masliah E. ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1753-67. PMID 25008355 DOI: 10.1038/Mt.2014.129 |
0.408 |
|
| 2014 |
Yang G, Velgos SN, Boddapati SP, Sierks MR. Probing antibody-antigen interactions Microbiology Spectrum. 2: 1-13. DOI: 10.1128/microbiolspec. AID-0010-2013 |
0.711 |
|
| 2013 |
Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M. Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. International Journal of Cell Biology. 2013: 260787. PMID 24159335 DOI: 10.1155/2013/260787 |
0.612 |
|
| 2013 |
Kasturirangan S, Reasoner T, Schulz P, Boddapati S, Emadi S, Valla J, Sierks MR. Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnology Progress. 29: 463-71. PMID 23359572 DOI: 10.1002/Btpr.1698 |
0.758 |
|
| 2012 |
Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR. Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP. Journal of Alzheimer's Disease : Jad. 28: 961-9. PMID 22156046 DOI: 10.3233/Jad-2011-111196 |
0.75 |
|
| 2012 |
Kasturirangan S, Li L, Emadi S, Boddapati S, Schulz P, Sierks MR. Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form. Neurobiology of Aging. 33: 1320-8. PMID 21067847 DOI: 10.1016/J.Neurobiolaging.2010.09.020 |
0.777 |
|
| 2012 |
Vattipalli K, Brandigampala S, McGraw C, Chatterjee G, Kasturirangan S, Schulz P, Sierks M, Prasad S. Nanotextured material for applications in CSF sample screening and characterization Materials Research Society Symposium Proceedings. 1466: 26-31. DOI: 10.1557/Opl.2012.1200 |
0.43 |
|
| 2011 |
Sierks MR, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integrative Biology : Quantitative Biosciences From Nano to Macro. 3: 1188-96. PMID 22076255 DOI: 10.1039/c1ib00018g |
0.434 |
|
| 2011 |
Boddapati S, Levites Y, Sierks MR. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. Journal of Molecular Biology. 405: 436-47. PMID 21073877 DOI: 10.1016/J.Jmb.2010.10.054 |
0.786 |
|
| 2010 |
Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. Bmc Neuroscience. 11: 57. PMID 20433710 DOI: 10.1186/1471-2202-11-57 |
0.707 |
|
| 2010 |
Kasturirangan S, Boddapati S, Sierks MR. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. Biochemistry. 49: 4501-8. PMID 20429609 DOI: 10.1021/Bi902030M |
0.78 |
|
| 2010 |
Wang MS, Boddapati S, Sierks MR. Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Biotechnology Progress. 26: 1172-9. PMID 20306540 DOI: 10.1002/Btpr.396 |
0.78 |
|
| 2010 |
Kasturirangan S, Sierks M. Targeted hydrolysis of beta-amyloid with engineered antibody fragments Current Alzheimer Research. 7: 214-222. PMID 20088808 DOI: 10.2174/156720510791050876 |
0.572 |
|
| 2009 |
Wang M, Boddapati S, Sierks M. Response letter to comments on "Cyclodextrins promote protein aggregation posing risks for therapeutic applications". Biochemical and Biophysical Research Communications. 390: 1426-7. PMID 19852940 DOI: 10.1016/J.Bbrc.2009.10.073 |
0.724 |
|
| 2009 |
Kasturirangan S, Brune D, Sierks M. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. Biotechnology Progress. 25: 1054-63. PMID 19572401 DOI: 10.1002/Btpr.190 |
0.416 |
|
| 2009 |
Wang MS, Boddapati S, Sierks MR. Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochemical and Biophysical Research Communications. 386: 526-31. PMID 19540204 DOI: 10.1016/J.Bbrc.2009.06.077 |
0.779 |
|
| 2009 |
Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. Plos One. 4: e5727. PMID 19492089 DOI: 10.1371/Journal.Pone.0005727 |
0.399 |
|
| 2009 |
Yuan B, Sierks MR. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neuroscience Letters. 459: 16-8. PMID 19394405 DOI: 10.1016/j.neulet.2009.04.046 |
0.31 |
|
| 2009 |
Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 918-29. PMID 19176801 DOI: 10.1523/Jneurosci.3952-08.2009 |
0.39 |
|
| 2009 |
Wang MS, Zameer A, Emadi S, Sierks MR. Characterizing antibody specificity to different protein morphologies by AFM. Langmuir : the Acs Journal of Surfaces and Colloids. 25: 912-8. PMID 19090748 DOI: 10.1021/la8025914 |
0.362 |
|
| 2008 |
Zameer A, Kasturirangan S, Emadi S, Nimmagadda SV, Sierks MR. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. Journal of Molecular Biology. 384: 917-28. PMID 18929576 DOI: 10.1016/j.jmb.2008.09.068 |
0.495 |
|
| 2008 |
Nannenga BL, Zameer A, Sierks MR. Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates. Febs Letters. 582: 517-22. PMID 18230361 DOI: 10.1016/J.Febslet.2008.01.014 |
0.353 |
|
| 2008 |
Marcus WD, Wang H, Lindsay SM, Sierks MR. Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy. Nanomedicine : Nanotechnology, Biology, and Medicine. 4: 1-7. PMID 18201941 DOI: 10.1016/j.nano.2007.11.003 |
0.419 |
|
| 2008 |
Boddapati SP, Sierks MR. P2-417: Beta-site specific ScFv's to decrease Abeta generation and toxicity in Alzheimer's disease Alzheimer's & Dementia. 4: T495-T496. DOI: 10.1016/J.Jalz.2008.05.1496 |
0.748 |
|
| 2007 |
Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. Journal of Molecular Biology. 368: 1132-44. PMID 17391701 DOI: 10.1016/j.jmb.2007.02.089 |
0.332 |
|
| 2006 |
Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 2576-8. PMID 17068112 DOI: 10.1096/Fj.06-6463Fje |
0.398 |
|
| 2006 |
Barkhordarian H, Emadi S, Schulz P, Sierks MR. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Engineering, Design & Selection : Peds. 19: 497-502. PMID 16984950 DOI: 10.1093/protein/gzl036 |
0.32 |
|
| 2006 |
Zameer A, Schulz P, Wang MS, Sierks MR. Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry. 45: 11532-9. PMID 16981713 DOI: 10.1021/bi060601o |
0.497 |
|
| 2006 |
Marcus WD, Wang H, Lohr D, Sierks MR, Lindsay SM. Isolation of an scFv targeting BRG1 using phage display with characterization by AFM. Biochemical and Biophysical Research Communications. 342: 1123-9. PMID 16513088 DOI: 10.1016/J.Bbrc.2006.02.073 |
0.345 |
|
| 2005 |
Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiology of Disease. 20: 74-81. PMID 16137568 DOI: 10.1016/j.nbd.2005.02.003 |
0.475 |
|
| 2005 |
Kanapathipillai M, Lentzen G, Sierks M, Park CB. Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid. Febs Letters. 579: 4775-80. PMID 16098972 DOI: 10.1016/J.Febslet.2005.07.057 |
0.559 |
|
| 2004 |
Liu R, McAllister C, Lyubchenko Y, Sierks MR. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry. 43: 9999-10007. PMID 15287727 DOI: 10.1021/Bi0492354 |
0.476 |
|
| 2004 |
Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, Lyubchenko Y, Goud G, Sierks MR. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry. 43: 6959-67. PMID 15170333 DOI: 10.1021/Bi049933O |
0.497 |
|
| 2004 |
Liu R, McAllister C, Lyubchenko Y, Sierks MR. Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. Journal of Neuroscience Research. 75: 162-71. PMID 14705137 DOI: 10.1002/Jnr.10859 |
0.442 |
|
| 2004 |
Zameer A, Liu R, Sierks M. P4-420 Single chain FV antibodies against 25–35 peptide fragment of amyloid-β: potential therapeutic for Alzheimers disease Neurobiology of Aging. 25: S593. DOI: 10.1016/S0197-4580(04)81976-6 |
0.47 |
|
| 2004 |
Liu R, Sierks M. P4-354 Anti beta-amyloid (Aβ) SCFV inhibits Aβ aggregation and neurotoxicity Neurobiology of Aging. 25: S575-S576. DOI: 10.1016/S0197-4580(04)81912-2 |
0.518 |
|
| 2004 |
Taguchi H, Planque S, Nishiyama Y, Sierks MR, Szabo P, Weksler ME, Paul S. P4-331 Catalytic hydrolysis of amyloid β-peptide (Aβ) by human antibodies Neurobiology of Aging. 25: S569. DOI: 10.1016/S0197-4580(04)81889-X |
0.343 |
|
| 2003 |
Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry. 42: 14328-34. PMID 14640701 DOI: 10.1021/bi035038d |
0.417 |
|
| 2001 |
Goud GN, Artsaenko O, Bols M, Sierks M. Specific glycosidase activity isolated from a random phage display antibody library Biotechnology Progress. 17: 197-202. PMID 11170499 DOI: 10.1021/Bp0001258 |
0.321 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2007 |
Shlyakhtenko LS, Yuan B, Emadi S, Lyubchenko YL, Sierks MR. Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy. Nanomedicine : Nanotechnology, Biology, and Medicine. 3: 192-7. PMID 17662669 DOI: 10.1016/j.nano.2007.06.001 |
0.293 |
|
| 2015 |
Xin W, Emadi S, Williams S, Liu Q, Schulz P, He P, Alam NB, Wu J, Sierks MR. Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell Models. Biomolecules. 5: 1634-51. PMID 26287258 DOI: 10.3390/biom5031634 |
0.287 |
|
| 2010 |
Kvam E, Sierks MR, Shoemaker CB, Messer A. Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Engineering, Design & Selection : Peds. 23: 489-98. PMID 20378699 DOI: 10.1093/Protein/Gzq022 |
0.286 |
|
| 2022 |
Cho HJ, Schulz P, Venkataraman L, Caselli RJ, Sierks MR. Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer's Disease. International Journal of Molecular Sciences. 23. PMID 36555310 DOI: 10.3390/ijms232415670 |
0.284 |
|
| 2015 |
Liu Q, Xie X, Emadi S, Sierks MR, Wu J. A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity. Neuropharmacology. 97: 457-63. PMID 25959067 DOI: 10.1016/J.Neuropharm.2015.04.025 |
0.283 |
|
| 2009 |
Emadi S, Kasturirangan S, Wang MS, Schulz P, Sierks MR. Detecting morphologically distinct oligomeric forms of alpha-synuclein. The Journal of Biological Chemistry. 284: 11048-58. PMID 19141614 DOI: 10.1074/jbc.M806559200 |
0.275 |
|
| 2018 |
Williams SM, Peltz C, Yaffe K, Schulz P, Sierks MR. CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury. Neurology. 91: 702-709. PMID 30297502 DOI: 10.1212/Wnl.0000000000006322 |
0.274 |
|
| 2008 |
Wang MS, Sierks MR. P1-496: Acidic pH effects on beta-amyloid aggregation and cytotoxicity Alzheimer's & Dementia. 4: T365-T365. DOI: 10.1016/j.jalz.2008.05.1079 |
0.272 |
|
| 2017 |
Williams SM, Khan G, Harris BT, Ravits J, Sierks MR. TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis. Bmc Neuroscience. 18: 20. PMID 28122516 DOI: 10.1186/S12868-017-0334-7 |
0.272 |
|
| 2006 |
Masson JF, Battaglia TM, Cramer J, Beaudoin S, Sierks M, Booksh KS. Reduction of nonspecific protein binding on surface plasmon resonance biosensors. Analytical and Bioanalytical Chemistry. 386: 1951-9. PMID 17086391 DOI: 10.1007/S00216-006-0834-2 |
0.266 |
|
| 2015 |
Liu Q, Xie X, Emadi S, Sierks MR, Wu J. A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity Neuropharmacology. 97: 457-463. DOI: 10.1016/j.neuropharm.2015.04.025 |
0.257 |
|
| 2004 |
Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y, Messer A, Sierks MR. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry. 43: 2871-8. PMID 15005622 DOI: 10.1021/Bi036281F |
0.255 |
|
| 2016 |
Spencer B, Williams S, Rockenstein E, Valera E, Xin W, Mante M, Florio J, Adame A, Masliah E, Sierks MR. α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Annals of Clinical and Translational Neurology. 3: 588-606. PMID 27606342 DOI: 10.1002/Acn3.321 |
0.248 |
|
| 1990 |
Evans R, Ford C, Sierks M, Nikolov Z, Svensson B. Activity and thermal stability of genetically truncated forms of Aspergillus glucoamylase Gene. 91: 131-134. PMID 2119327 DOI: 10.1016/0378-1119(90)90174-P |
0.237 |
|
| 2006 |
Yuan B, Schulz P, Liu R, Sierks MR. Improved affinity selection using phage display technology and off-rate based selection Electronic Journal of Biotechnology. 9: 171-175. DOI: 10.2225/vol9-issue2-fulltext-6 |
0.222 |
|
| 1998 |
Wu H, Goud GN, Sierks MR. Artificial antibodies for affinity chromatography of homologous proteins: Application to blood clotting proteins Biotechnology Progress. 14: 496-499. PMID 9622533 DOI: 10.1021/bp980017+ |
0.218 |
|
| 1989 |
Svensson B, Jespersen H, Sierks MR, MacGregor EA. Sequence homology between putative raw-starch binding domains from different starch-degrading enzymes Biochemical Journal. 264: 309-311. PMID 2481445 DOI: 10.1042/Bj2640309 |
0.217 |
|
| 2014 |
Cardinale A, Chiesa R, Sierks M. Protein misfolding and neurodegenerative diseases. International Journal of Cell Biology. 2014: 217371. PMID 24799906 DOI: 10.1155/2014/217371 |
0.217 |
|
| 2006 |
Marcus WD, Lindsay SM, Sierks MR. Identification and repair of positive binding antibodies containing randomly generated amber codons from synthetic phage display libraries. Biotechnology Progress. 22: 919-22. PMID 16739981 DOI: 10.1021/bp050420y |
0.212 |
|
| 2004 |
Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1023-31. PMID 15564134 DOI: 10.1016/J.Ymthe.2004.08.019 |
0.199 |
|
| 2013 |
Liu Q, Emadi S, Shen JX, Sierks MR, Wu J. Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein. Plos One. 8: e55886. PMID 23437071 DOI: 10.1371/Journal.Pone.0055886 |
0.199 |
|
| 2015 |
Williams S, Schulz P, Sierks MR. A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples. Biotechnology Progress. 31: 289-98. PMID 25203940 DOI: 10.1002/btpr.1987 |
0.189 |
|
| 1996 |
Dong W, Jespersen T, Bols M, Skrydstrup T, Sierks MR. Evaluation of isofagomine and its derivatives as potent glycosidase inhibitors Biochemistry. 35: 2788-2795. PMID 8611585 DOI: 10.1021/Bi9522514 |
0.147 |
|
| 1985 |
Sierks MR, Reilly PJ. Application of cross-linked carboxymethyl cellulose degradation by β-glucosidase and vaginal microbes to toxic shock syndrome Applied and Environmental Microbiology. 50: 634-637. PMID 3935049 |
0.136 |
|
| 1992 |
Svensson B, Sierks MR. Roles of the aromatic side chains in the binding of substrates, inhibitors, and cyclomalto-oligosaccharides to the glucoamylase from Aspergillus niger probed by perturbation difference spectroscopy, chemical modification, and mutagenesis Carbohydrate Research. 227: 29-44. PMID 1499029 DOI: 10.1016/0008-6215(92)85059-9 |
0.134 |
|
| 1995 |
Barbaud C, Bols M, Lundt I, Sierks MR. Synthesis of the first pseudosugar-C-disaccharide. A potential antigen for eliciting glycoside-bond forming antibodies with catalytic groups Tetrahedron. 51: 9063-9078. DOI: 10.1016/0040-4020(95)00505-3 |
0.117 |
|
| 1993 |
Jespersen HM, Ann MacGregor E, Henrissat B, Sierks MR, Svensson B. Starch- and glycogen-debranching and branching enzymes: Prediction of structural features of the catalytic (β/α)8-barrel domain and evolutionary relationship to other amylolytic enzymes Journal of Protein Chemistry. 12: 791-805. PMID 8136030 DOI: 10.1007/BF01024938 |
0.108 |
|
| 1994 |
Sierks MR. Protein engineering of the relative specificity of glucoamylase from aspergillus awamori based on sequence similarities between starchdegrading enzymes Protein Engineering, Design and Selection. 7: 1479-1484. PMID 7716159 DOI: 10.1093/protein/7.12.1479 |
0.108 |
|
| 1993 |
Sierks MR, Ford C, Reilly PJ, Svensson B. Functional roles and subsite locations of leu177, trp178 and asn182 of Aspergillus awamori glucoamylase determined by site-directed mutagenesis Protein Engineering, Design and Selection. 6: 75-79. PMID 8433972 DOI: 10.1093/protein/6.1.75 |
0.106 |
|
| 1993 |
Sierks MR, Svensson B. Functional roles of the invariant aspartic acid 55, tyrosine 306, and aspartic acid 309 in glucoamylase from Aspergillus awamori studied by mutagenesis Biochemistry. 32: 1113-1117. PMID 8424940 |
0.103 |
|
| 1991 |
Jespersen HM, MacGregor EA, Sierks MR, Svensson B. Comparison of the domain-level organization of starch hydrolases and related enzymes Biochemical Journal. 280: 51-55. PMID 1741756 |
0.099 |
|
| 1990 |
Sierks MR, Ford C, Reilly PJ, Svensson B. Catalytic mechanism of fungal glucoamylase as defined by mutagenesis of asp176, glu179 and glu180 in the enzyme from Aspergillus awamori Protein Engineering, Design and Selection. 3: 193-198. PMID 1970434 DOI: 10.1093/protein/3.3.193 |
0.094 |
|
| 1996 |
Natarajan S, Sierks MR. Functional and structural roles of the highly conserved Trp120 loop region of glucoamylase from Aspergillus awamori Biochemistry. 35: 3050-3058. PMID 8608145 DOI: 10.1021/bi952458x |
0.089 |
|
| 1989 |
Sierks MR, Ford C, Reilly PJ, Svensson B. Site-directed mutagenesis at the active site Trpl20 of Aspergillus awamori glucoamylase Protein Engineering, Design and Selection. 2: 621-625. PMID 2510150 DOI: 10.1093/protein/2.8.621 |
0.089 |
|
| 2005 |
Battaglia TM, Masson JF, Sierks MR, Beaudoin SP, Rogers J, Foster KN, Holloway GA, Booksh KS. Quantification of cytokines involved in wound healing using surface plasmon resonance. Analytical Chemistry. 77: 7016-23. PMID 16255604 DOI: 10.1021/Ac050568W |
0.086 |
|
| 2000 |
Sierks MR, Svensson B. Energetic and mechanistic studies of glucoamylase using molecular recognition of maltose OH groups coupled with site-directed mutagenesis Biochemistry. 39: 8585-8592. PMID 10913265 DOI: 10.1021/bi9925219 |
0.084 |
|
| 1996 |
Sierks MR, Svensson B. Catalytic mechanism of glucoamylase probed by mutagenesis in conjunction with hydrolysis of α-D-glucopyranosyl fluoride and maltooligosaccharides Biochemistry. 35: 1865-1871. PMID 8639668 DOI: 10.1021/bi951738+ |
0.082 |
|
| 1997 |
Natarajan SK, Sierks MR. Minimizing nonproductive substrate binding: A new look at glucoamylase subsite affinities Biochemistry. 36: 14946-14955. PMID 9398219 DOI: 10.1021/bi970820x |
0.08 |
|
| 1995 |
Mikkelsen G, Christensen TV, Bols M, Lundt I, Sierks MR. Aglycon mimicking: Glycoside bond cleavage transition state mimics based on hydroxypyrrolidine inhibitors Tetrahedron Letters. 36: 6541-6544. DOI: 10.1016/0040-4039(95)01281-L |
0.079 |
|
| 1994 |
Frandsen TP, Dupont C, Lehmbeck J, Stoffer B, Sierks MR, Honzatko RB, Svensson B. Site-directed mutagenesis of the catalytic base glutamic acid 400 in glucoamylase from Aspergillus niger and of tyrosine 48 and glutamine 401, both hydrogen-bonded to the γ-carboxylate group of glutamic acid 400 Biochemistry. 33: 13808-13816. PMID 7947792 DOI: 10.1021/Bi00250A035 |
0.072 |
|
| 1992 |
Sierks MR, Svensson B. Kinetic identification of a hydrogen bonding pair in the glucoamylase-maltose transition state complex Protein Engineering, Design and Selection. 5: 185-188. PMID 1350675 DOI: 10.1093/protein/5.2.185 |
0.069 |
|
| 1992 |
Sierks MR, Bock K, Refn S, Svensson B. Active site similarities of glucose dehydrogenase, glucose oxidase, and glucoamylase probed by deoxygenated substrates Biochemistry. 31: 8972-8977. PMID 1390684 DOI: 10.1021/Bi00152A038 |
0.059 |
|
| 1997 |
Sierks MR, Sico C, Zaw M. Solvent and viscosity effects on the rate-limiting product release step of glucoamylase during maltose hydrolysis Biotechnology Progress. 13: 601-608. PMID 9336980 DOI: 10.1021/bp9700824 |
0.057 |
|
| 1993 |
Olsen K, Christensen U, Sierks MR, Svensson B. Reaction mechanisms of Trp120→Phe and wild-type glucoamylases from Aspergillus niger. Interactions with maltooligodextrins and acarbose Biochemistry. 32: 9686-9693. PMID 8373772 |
0.053 |
|
| 1996 |
Natarajan SK, Sierks MR. Identification of enzyme-substrate and enzyme-product complexes in the catalytic mechanism of glucoamylase from Aspergillus awamori Biochemistry. 35: 15269-15279. PMID 8952477 DOI: 10.1021/bi961355r |
0.051 |
|
| 2010 |
JESPERSEN TM, BOLS M, SIERKS MR, SKRYDSTRUP T. ChemInform Abstract: Synthesis of Isofagomine, a Novel Glycosidase Inhibitor. Cheminform. 26: no-no. DOI: 10.1002/chin.199519211 |
0.046 |
|
| 1994 |
Jespersen TM, Dong W, Sierks MR, Skrydstrup T, Lundt I, Bols M. Isofagomine, a potent, new glycosidase inhibitor Angewandte Chemie (International Edition in English). 33: 1778-1779. DOI: 10.1002/Anie.199417781 |
0.036 |
|
| 2001 |
Ferreira GM, Ahuja SK, Sierks MR, Moreira AR. Pleomorphism of the marine bacterium Teredinobacter turnirae. Letters in Applied Microbiology. 33: 56-60. PMID 11442816 DOI: 10.1046/j.1472-765X.2001.00951.x |
0.023 |
|
| 1994 |
Jespersen TM, Dong W, Sierks MR, Skrydstrup T, Lundt I, Bols M. Isofagomin, ein wirksamer neuer Glycosidaseinhibitor Angewandte Chemie. 106: 1858-1860. DOI: 10.1002/Ange.19941061730 |
0.01 |
|
| Hide low-probability matches. |
